Drug Discovery
11 articles
7 AI Advancements for Drug Discovery and Development
Artificial intelligence identified a novel liver cancer drug candidate in just 30 days, a speed traditionally achieved over years.
AI Advancements Revolutionizing Regenerative Medicine
Insilico Medicine's Rentosertib, an oral small-molecule inhibitor for idiopathic pulmonary fibrosis (IPF), progressed from discovery to a Phase III clinical trial in record time.
How AI Models Are Accelerating Scientific Discovery
AI has already helped identify two new compounds effective against drug-resistant gonorrhoea and MRSA, targeting bacteria in novel ways previously undiscovered.
Insilico and SK Biopharm Advance AI Drug Discovery
Insilico Medicine's lead drug, INS018_055, reached Phase II trials in 2026, marking it as the first generative AI-designed drug for an AI-discovered target to achieve this milestone.
Altaris Capital Buys Simulations Plus for $375 Million
Simulations Plus shareholders will receive $18.
How AI is Accelerating Drug Discovery and Vaccine Development
In a remarkable acceleration, AI helped Insilico achieve a 30-month sprint from target identification to a Phase I clinical trial candidate, a process that traditionally takes years longer, according
Reid Hoffman to leave Microsoft board in 2026 for AI startup
On June 2, Reid Hoffman formally notified Microsoft he would not seek re-election to its board in 2026.
8 AI Applications Revolutionizing Healthcare in 2026
In a significant breakthrough against antibiotic resistance, artificial intelligence has identified two new compounds effective against drug-resistant gonorrhoea and MRSA.
How AI and QSAR Modeling Accelerate Ligand-Based Drug Design
In a quantitative structure-activity relationship (QSAR)-guided design task for EGFR, ChatGPT generated molecules with estimated IC50 values of approximately 10–50 nM after two iterations, starting fr
How Machine Learning Speeds Drug Discovery in Clinical Trials
80% of clinical trials miss their timelines, imposing daily costs of up to $8 million on pharmaceutical companies, according to Nature .
Boehringer Ingelheim to Establish London AI Center
Boehringer Ingelheim is committing £150 million over the next decade to establish a new artificial intelligence and machine learning center in London, aiming to staff it with 50 experts by 2027, accor